Compare XPL & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPL | OKYO |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.7M | 71.4M |
| IPO Year | 2000 | 2021 |
| Metric | XPL | OKYO |
|---|---|---|
| Price | $0.47 | $1.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.50 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 89.9K | 57.1K |
| Earning Date | 11-03-2026 | 07-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $1.26 |
| 52 Week High | $0.98 | $3.20 |
| Indicator | XPL | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 25.16 | 53.46 |
| Support Level | N/A | $1.29 |
| Resistance Level | $0.82 | $1.72 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 15.44 | 38.36 |
Solitario Resources Corp is an exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. Its core mineral property assets are: the Florida Canyon zinc project in Peru, the Lik zinc project in Alaska, and the Golden Crest project in South Dakota. Additionally, Solitario holds an interest in the Chambara project in Peru and also has two early-stage projects, the Cat Creek project and the Bright Angel project in Colorado. The company is conducting mineral exploration on its Golden Crest project, the Cat Creek project, and the Bright Angel project on its own.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.